No, not buy them, just a wild guess at licensing their INNO-406 asset, which has already gone through toxicology and human clinical trials for cancer, but can most likely be repurposed in Parkinson's with funding through MJFF grants. The tyrosine kinase inhibitor mechanism appears to warrant great possibilities. The owner of the asset had stated they wanted to license/partner INNO-406, but that was for cancer. Makes more sense for them to move it into Parkinson's trials themselves.
If AMBS is making another acquisition, this is my guess.
News 
Market Data 
Discover 
